Cloak and dagger in the avoidance of immune surveillance

Pinkoski, 1999, Fas ligand, death gene, Cell Death Differ, 6, 1174, 10.1038/sj.cdd.4400611 Hunig, 1997, Systemic autoimmune disease as a consequence of defective lymphocyte death, Curr Opin Immunol, 9, 826, 10.1016/S0952-7915(97)80185-9 Green, 1998, Apoptotic pathways: the roads to ruin, Cell, 94, 695, 10.1016/S0092-8674(00)81728-6 Ashkenazi, 1998, Death receptors: signaling and modulation, Science, 281, 1305, 10.1126/science.281.5381.1305 Wolf, 1999, Suicidal tendencies: apoptotic cell death by caspase family proteinases, J Biol Chem, 274, 20049, 10.1074/jbc.274.29.20049 Thornberry, 1998, Caspases: enemies within, Science, 281, 1312, 10.1126/science.281.5381.1312 Walker, 1998, Tumor expression of Fas ligand (CD95L) and the consequences, Curr Opin Immunol, 10, 564, 10.1016/S0952-7915(98)80225-2 O’Connell, 1999, The Fas counterattack: cancer as a site of immune privilege, Immunol Today, 20, 46, 10.1016/S0167-5699(98)01382-6 French, 1996, Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover, J Cell Biol, 133, 335, 10.1083/jcb.133.2.335 Owen-Schaub, 1998, Fas and Fas ligand interactions suppress melanoma lung metastasis, J Exp Med, 188, 1717, 10.1084/jem.188.9.1717 Peli, 1999, Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas, EMBO J, 18, 1824, 10.1093/emboj/18.7.1824 Downward, 1998, Ras signalling and apoptosis, Curr Opin Genet Dev, 8, 49, 10.1016/S0959-437X(98)80061-0 Hueber, 1997, Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis, Science, 278, 1305, 10.1126/science.278.5341.1305 Pelengaris, 1999, Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion, Mol Cell, 3, 565, 10.1016/S1097-2765(00)80350-0 Hill, 1999, Fas ligand: a sensor for DNA damage critical in skin cancer etiology, Science, 285, 898, 10.1126/science.285.5429.898 Hill, 1999, A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation, J Exp Med, 189, 1285, 10.1084/jem.189.8.1285 Levine, 1997, p53, the cellular gatekeeper for growth and division, Cell, 88, 323, 10.1016/S0092-8674(00)81871-1 Bennett, 1998, Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis, Science, 282, 290, 10.1126/science.282.5387.290 Soengas, 1999, Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition, Science, 284, 156, 10.1126/science.284.5411.156 Pitti, 1998, Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer, Nature, 396, 699, 10.1038/25387 Takahashi, 1994, Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand, Cell, 76, 969, 10.1016/0092-8674(94)90375-1 Watanabe-Fukunaga, 1992, Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis, Nature, 356, 314, 10.1038/356314a0 Fisher, 1995, Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome, Cell, 81, 935, 10.1016/0092-8674(95)90013-6 Wu, 1996, Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease, J Clin Invest, 98, 1107, 10.1172/JCI118892 Wang, 1999, Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II, Cell, 98, 47, 10.1016/S0092-8674(00)80605-4 Stambolic, 1998, Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN, Cell, 95, 29, 10.1016/S0092-8674(00)81780-8 Haas-Kogan, 1998, Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC, Curr Biol, 8, 1195, 10.1016/S0960-9822(07)00493-9 Suzuki, 1998, High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice, Curr Biol, 8, 1169, 10.1016/S0960-9822(07)00488-5 Cardone, 1998, Regulation of cell death protease caspase-9 by phosphorylation, Science, 282, 1318, 10.1126/science.282.5392.1318 Maehama, 1999, PTEN: a tumour suppressor that functions as a phospholipid phosphatase, Trends Cell Biol, 9, 125, 10.1016/S0962-8924(99)01519-6 Leevers, 1999, Signalling through phosphoinositide 3-kinases: the lipids take centre stage, Curr Opin Cell Biol, 11, 219, 10.1016/S0955-0674(99)80029-5 Cantley, 1999, New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway, Proc Natl Acad Sci USA, 96, 4240, 10.1073/pnas.96.8.4240 Di Cristofano, 1999, Impaired Fas response and autoimmunity in Pten(+/−) mice, Science, 285, 2122, 10.1126/science.285.5436.2122 Dhein, 1995, Autocrine T-cell suicide mediated by APO-1/(Fas/CD95), Nature, 373, 438, 10.1038/373438a0 Ju, 1995, Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation, Nature, 373, 444, 10.1038/373444a0 Brunner, 1995, Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas, Nature, 373, 441, 10.1038/373441a0 Genestier, 1999, Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc, J Exp Med, 189, 231, 10.1084/jem.189.2.231 Hildeman, 1999, Reactive oxygen species regulate activation-induced T cell apoptosis, Immunity, 10, 735, 10.1016/S1074-7613(00)80072-2 Bonfoco, 1998, Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells, Immunity, 9, 711, 10.1016/S1074-7613(00)80668-8 Green, 1997, Fas-ligand: privilege and peril, Proc Natl Acad Sci USA, 94, 5986, 10.1073/pnas.94.12.5986 Ferguson, 1997, A vision of cell death: insights into immune privilege, Immunol Rev, 156, 167, 10.1111/j.1600-065X.1997.tb00967.x Chen, 1998, Regulation of the proinflammatory effects of Fas ligand (CD95L), Science, 282, 1714, 10.1126/science.282.5394.1714 Allison, 1997, Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts, Proc Natl Acad Sci USA, 94, 3943, 10.1073/pnas.94.8.3943 Takeuchi, 1999, Accelerated rejection of Fas ligand-expressing heart grafts, J Immunol, 162, 518, 10.4049/jimmunol.162.1.518 Kang, 1997, Immune response and myoblasts that express Fas ligand, Science, 278, 1322, 10.1126/science.278.5341.1322 Gao, 1998, Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis, J Exp Med, 188, 887, 10.1084/jem.188.5.887 Tanaka, 1998, Downregulation of Fas ligand by shedding, Nat Med, 4, 31, 10.1038/nm0198-031 Schneider, 1998, Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity, J Exp Med, 187, 1205, 10.1084/jem.187.8.1205 Mitsiades, 1998, Fas ligand is present in tumors of the Ewing’s sarcoma family and is cleaved into a soluble form by a metalloproteinase, Am J Pathol, 153, 1947, 10.1016/S0002-9440(10)65708-2 Ottonello, 1999, Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes, J Immunol, 162, 3601, 10.4049/jimmunol.162.6.3601 Liles, 1996, Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils, J Exp Med, 184, 429, 10.1084/jem.184.2.429